25.09
2.11%
-0.545
전일 마감가:
$25.64
열려 있는:
$25.37
하루 거래량:
208.32K
Relative Volume:
0.98
시가총액:
$1.69B
수익:
$286.00M
순이익/손실:
$305.47M
주가수익비율:
-10.71
EPS:
-2.3434
순현금흐름:
$-492.33M
1주 성능:
-10.04%
1개월 성능:
-19.16%
6개월 성능:
-11.56%
1년 성능:
-31.92%
갈라파고스 ADR Stock (GLPG) Company Profile
GLPG을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
GLPG | 25.10 | 1.69B | 286.00M | 305.47M | -492.33M | -2.3434 |
VRTX | 449.90 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.15 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 595.64 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.18 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.10 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
갈라파고스 ADR Stock (GLPG) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-09-09 | 개시 | Leerink Partners | Market Perform |
2024-08-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2024-03-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
2023-08-24 | 다운그레이드 | Citigroup | Buy → Neutral |
2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2023-01-23 | 업그레이드 | Jefferies | Underperform → Hold |
2022-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-01-27 | 업그레이드 | Citigroup | Neutral → Buy |
2021-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2021-08-06 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2021-04-20 | 개시 | Deutsche Bank | Buy |
2021-04-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
2021-02-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
2021-02-19 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-11-19 | 개시 | Maxim Group | Buy |
2020-10-21 | 다운그레이드 | Goldman | Neutral → Sell |
2020-08-25 | 다운그레이드 | Jefferies | Buy → Hold |
2020-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
2020-07-10 | 다운그레이드 | Stifel | Buy → Hold |
2020-03-30 | 업그레이드 | Jefferies | Hold → Buy |
2020-03-18 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
2020-02-25 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2020-02-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
2020-02-20 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
2020-01-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-12-18 | 다운그레이드 | Citigroup | Buy → Neutral |
2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2019-12-02 | 개시 | BofA/Merrill | Neutral |
2019-09-09 | 재개 | Morgan Stanley | Overweight |
2019-07-31 | 업그레이드 | UBS | Neutral → Buy |
2019-07-29 | 다운그레이드 | Jefferies | Buy → Hold |
모두보기
갈라파고스 ADR 주식(GLPG)의 최신 뉴스
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Are Medical Stocks Lagging Galapagos (GLPG) This Year? - Yahoo Singapore News
Earnings call: Galapagos outlines strategic focus in Q1 2024 results By Investing.com - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos Surges On New CEO and Upgrade News - Investing.com
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integr - Benzinga
Is Galapagos NV (GLPG) A Good Stock To Buy? - Insider Monkey
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes DividendAlecto - Benzinga
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To DebutStaar S - Benzinga
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOsAmarin Corp (NASDAQ:A - Benzinga
AIM tech shares that broke America - Interactive Investor
25 Stocks Moving In Friday's Pre-Market SessionAlnylam Pharmaceuticals (NASDAQ:ALNY), Aclaris Therapeu - Benzinga
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - InvestorPlace
갈라파고스 ADR (GLPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):